Primary Site >> Colorectal Cancer
Gene >> ERCC2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. PMID: 9485007 |
Ref: Hepatitis B virus X protein inhibits nucleotide excision repair. PMID: 10074921 |
Ref: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. PMID: 10655513 |
Ref: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. PMID: 11751380 |
Ref: Implications of genetic testing in the management of colorectal cancer. PMID: 12749725 Ref: Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. PMID: 12865926 |
Ref: Genotype phenotype correlations in Israeli colorectal cancer patients. PMID: 15523694 Ref: Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan. PMID: 15679883 |
Ref: Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. PMID: 16542436 Ref: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. PMID: 16609022 Ref: Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. PMID: 16773204 |
Ref: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. PMID: 17401013 Ref: Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. PMID: 18085999 |
Ref: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. PMID: 17549067 Ref: ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. PMID: 18267032 Ref: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. PMID: 18509181 Ref: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. PMID: 18797464 |
Ref: Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. PMID: 19432884 Ref: Common polymorphisms in the XPD and hOGG1 genes are not associated with the risk of colorectal cancer in a Polish population. PMID: 19561388 Ref: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. PMID: 19858398 |
Ref: The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. PMID: 19908066 Ref: Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. PMID: 19922504 Ref: Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. PMID: 20020129 Ref: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. PMID: 20078613 Ref: Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk: a case-control study in an Indian population. PMID: 20229274 Ref: Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. PMID: 20504250 Ref: Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. PMID: 20720310 |
Ref: ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. PMID: 21278243 Ref: Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies. PMID: 21541661 Ref: Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population. PMID: 21561390 Ref: Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? PMID: 21958378 |
Ref: Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls. PMID: 22294771 Ref: Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. PMID: 22909207 Ref: Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. PMID: 22966016 Ref: [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients]. PMID: 22967467 Ref: GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. PMID: 22994779 Ref: ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis. PMID: 24833529 |
Ref: Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. PMID: 23096768 Ref: Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. PMID: 23314736 Ref: Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. PMID: 23332421 Ref: Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome. PMID: 23429196 Ref: Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. PMID: 23543295 Ref: The influence of XPD, APE1, XRCC1, and NBS1 polymorphic variants on DNA repair in cells exposed to X-rays. PMID: 23669291 Ref: Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. PMID: 23996617 Ref: Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. PMID: 24137384 Ref: Lys751Gln XPD and Arg399Gln XRCC1 in Romanians. Association with sporadic colorectal cancer risk and different stages of carcinomas. PMID: 24157118 |
Ref: Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population. PMID: 24531312 Ref: The effect of XPD polymorphisms on digestive tract cancers risk: a meta-analysis. PMID: 24787743 Ref: Lack of association between the XPD Lys751Gln polymorphism and colorectal cancer risk: a meta-analysis. PMID: 25050067 Ref: Meat-derived carcinogens, genetic susceptibility and colorectal adenoma risk. PMID: 25231222 Ref: Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. PMID: 25370899 Ref: The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: a systemic review and meta-analysis. PMID: 25520091 |
Ref: Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population. PMID: 25391773 Ref: Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. PMID: 25677447 Ref: DNA repair gene polymorphisms do not predict response to radiotherapy-based multimodality treatment of patients with rectal cancer: a meta-analysis. PMID: 25684513 Ref: An association of selected ERCC2 and ERCC5 genes polymorphisms, the level of oxidative DNA damage and its repair efficiency with a risk of colorectal cancer in Polish population. PMID: 25835182 |
Ref: Contribution of DNA Repair Xeroderma Pigmentosum Group D Genotypes to Colorectal Cancer Risk in Taiwan. PMID: 27069143 Ref: Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. PMID: 27636246 Ref: DNA repair genes polymorphisms and risk of colorectal cancer in Saudi patients. PMID: 27686263 |
Ref: ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. PMID: 28088319 Ref: Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. PMID: 28608017 |
Ref: The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis. PMID: 29568775 Ref: Polymorphisms of DNA repair genes are associated with colorectal cancer in patients with Lynch syndrome. PMID: 29664240 |